AlphAIalphai — Financial news for AI agents
tradingview.comSEP 12 min read$AXSM

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

Axsome Therapeutics (AXSM) began a phase III study for AXS-05 in smoking cessation. The SUMMIT study will evaluate safety and efficacy over 12 weeks. Auvelity (AXS-05) sales reached $333M in H1 2026, up 54.2% YoY. Sunosi and Symbravo also contributed to revenue growth. AXSM shares rose 8.7% YTD.

Original reporting
tradingview.com
Published Sep 1, 2026, 4:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 1:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation — source image
Source · tradingview.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

The Phase III start signals progression toward a new revenue stream if the smoking cessation indication succeeds.

02

Market read

First-in-human dosing in a pivotal trial is a key catalyst for biotech stocks, likely to drive short-term interest.

03

What to watch

Potential competition from other smoking cessation therapies and regulatory timelines.

Relevance 8/10Novelty 9/10Timing: first patient dosed today

Background

Axsome already markets Auvelity for depression and has recently expanded its portfolio with Sunosi and Symbravo.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Axsome Therapeutics dosed the first patient in the Phase III SUMMIT study for smoking cessation.

Expected impact

Potential upside as data readouts approach; short-term volatility expected.

Evidence & confidence

Phase III initiation is a material event for a biotech; investors typically price in trial progress.

Market effects

Sector

Adds momentum to the psychiatric/neurology biotech sector as a new indication is explored.

Regional

Limited to US biotech investors; no broad regional effect.

Global

Modest global relevance, primarily for investors tracking US-listed biotech pipelines.

Counterpoint

What could challenge this read

If the trial fails to meet endpoints, the stock could sharply decline, making the current hype risky.

Key entities

  • company
    Axsome Therapeutics

    US-listed biotech developing AXS-05.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min
AUG 11
$AXSMMed

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics (AXSM) reported Q2 updates on AUVELITY, SYMBRAVO, and SUNOSI, including gross-to-net discounts and prescription growth. AUVELITY was launched for Alzheimer’s agitation, with total prescriptions about 266,000. SYMBRAVO prescriptions rose to about 23,500. FDA accepted AXS-12 NDA with a May 1, 2027 target date. Costs and expenses were also detailed.

yahoo.com6 min
AUG 11
$ABXMed

Barrick Profit Soars, Nvidia Eyes $500B AI Push, M&A Accelerates

The article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.

hdfcsky.com7 min